期刊
INTERNATIONAL JOURNAL OF PHARMACEUTICS
卷 600, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ijpharm.2021.120461
关键词
Inflammatory bowel disease; Oral administration; Nano-delivery systems; Mechanisms; Targeting strategies
资金
- Science and Technology Commission of Shanghai Municipality [18ZR1404100]
- Shanghai Pujiang Program [18PJD001]
- National Natural Science Foundation of China [81872826]
Inflammatory bowel disease is a chronic inflammatory disorder of the gastrointestinal tract with increasing incidence. Current treatments are associated with significant adverse effects and limited efficacy. Using oral nano-drug delivery systems for targeted therapy can reduce systemic absorption, increase local drug concentration, and improve therapeutic outcomes.
Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory disorder of gastrointestinal tract with rising incidence. Established treatments of IBD are characterized by significantly adverse effects, insufficient therapeutic efficacy. Employing the oral nano-drug delivery systems for targeted therapy is capable of effectively avoiding systematic absorption and increasing local drug concentration, consequently leading to decreased adverse effects and improved therapeutic outcomes. This review gives a brief profile of pathophysiological considerations in terms of developing disease-directed drug delivery systems, then focuses on mechanisms and strategies of current oral nano-drug delivery systems, including size-, enzyme-, redox-, pH-, ligand-receptor-, mucus-dependent systems, and proposes the future directions of managements for IBD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据